VM-902A pharmaceutical product. The asset is used to develop VM-902A which is orally bioavailable, peripherally acting and allosteric selective tropomyosin receptor kinase for recovering of many diseases in USA.
What you see here scratches the surface
We’ll help you find what you need
This information is available in the PitchBook Platform. To explore VM Pharma (TrkA Program)‘s full profile, request access.
© 2020 PitchBook Data. All rights reserved. PitchBook is a financial technology company that provides data on the capital markets.